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Edwardsiella tarda is a Gram-negative enteric pathogen that causes hemorrhagic septicemia in fish and
both gastrointestinal and extraintestinal infections in humans. A type III secretion system (T3SS) was
recently shown to contribute to pathogenesis, since deletions of various T3SS genes increased the 50%
lethal dose (LD50) by about 1 log unit in the blue gourami infection model. In this study, we report EseG
as the first identified effector protein of T3SS. EseG shares partial homology with two Salmonella T3SS
effectors (SseG and SseF) over a conserved domain (amino acid residues 142 to 192). The secretion of
EseG is dependent on a functional T3SS and, in particular, requires the chaperone EscB. Experiments
using TEM-1 -lactamase as a fluorescence-based reporter showed that EseG was translocated into HeLa
cells at 35°C. Fractionation of infected HeLa cells demonstrated that EseG was localized to the host
membrane fraction after translocation. EseG is able to disassemble microtubule structures when overex-
pressed in mammalian cells. This phenotype may require a conserved motif of EseG (EseG142–192), since
truncated versions of EseG devoid of this motif lose their ability to cause microtubule destabilization. By
demonstrating the function of EseG, our study contributes to the understanding of E. tarda pathogenesis.
Moreover, the approach established in this study to identify type III effectors can be used to identify and
characterize more type III and possible type VI effectors in Edwardsiella.
Edwardsiella tarda is a Gram-negative bacterium associ-
ated with septicemia and fatal infections in many animals,
including fish and humans (18, 36, 48). In humans, it causes
gastrointestinal infections as well as extraintestinal infec-
tions such as myonecrosis, bacteremia, septic arthritis, and
wound infections (18). Using a comparative proteomics ap-
proach, our group reported the presence of two secretion
systems, namely, a type III secretion system (T3SS) and a
type VI secretion system (T6SS), which are vital for E. tarda
pathogenesis (44, 45, 46, 54).
T3SSs are contact-dependent translocation systems that
have been found in many Gram-negative bacteria of ani-
mals, commensals, and plant-symbiotic rhizobia (3, 31).
They have many components, such as secretion and trans-
locon apparatuses, effectors, regulators, and chaperones.
The protein secretion machinery directs the secretion and
translocation of many bacterial effectors into host cells. The
concerted action of these effectors stimulates or interferes
with host cellular processes, thereby dictating the terms of
bacterium-host cell interactions (8). In Salmonella spp.,
more than 30 effectors are secreted by two different T3SSs.
These effectors are involved in several diverse functions,
such as forced entry into epithelial cells, intracellular repli-
cation inside vacuoles, and suppression of cellular immune
responses (16, 29, 50). In Yersinia species, six Yop effectors
have been identified, and they have been found to disrupt
vital signaling cascades that are required for innate immu-
nity (20, 41). T3SS effectors are generally less conserved
than other components of T3SSs, and they perform unique
functions adapted to a pathogen’s virulence strategy.
The T3SS facilitates the survival of E. tarda in phagocytes
and HEp-2 cells (19, 33, 34, 45) and contributes to virulence in
vivo (45). The deletion of various single T3SS genes, such as
escC, eseB, eseD, or escA, increased the 50% lethal dose (LD50)
by approximately 1 log unit in blue gourami (49, 55). EscC has
been shown to act as the chaperone for EseB and EseD,
whereas EscA is the chaperone for EseC (49, 55). EseB, EseC,
and EseD, which are secreted in large quantities by E. tarda,
are homologous to Salmonella sp. SseB, SseC, and SseD, re-
spectively (45). The SseB, SseC, and SseD proteins are se-
creted by the T3SS of Salmonella pathogenicity island 2 (SPI-2)
and predominantly assemble into complexes (SseBCD) that
function as a translocon for effector proteins (32). EseB, EseC,
and EseD can also form a protein complex (EseBCD) after
secretion (55), suggesting that the EseBCD complex functions
as a translocon component, rather than as T3SS effectors. To
our knowledge, no T3SS effectors have been identified in E.
tarda yet.
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The E. tarda T3SS has almost a full set of genes that are
homologous to those of SPI-2 (45). A bioinformatics analysis
of E. tarda T3SS proteins revealed that EseG bears some
similarity to two Salmonella effectors, SseG and SseF. SseG is
an effector of SPI-2 that targets intracellular Salmonella to the
Golgi network, where the close association of bacterial cells
allows Salmonella to multiply efficiently (40). SseF, another
SPI-2 effector, is involved in positioning and maintaining the
Salmonella-containing vacuoles (SCV) in a juxtanuclear posi-
tion in infected epithelial cells (1). The translocated Salmo-
nella effector proteins SseF and SseG interact with each other
and are required for Salmonella to establish an intracellular
replication niche (12).
In this study, we used a modified TEM-1 -lactamase system
(TEM) to show that EseG is an E. tarda T3SS effector that is
localized in the host membrane fraction after translocation. A
functional study showed that EseG interacts with -tubulin and
destabilizes the microtubule through a conserved domain. The
eseG mutant showed slightly reduced virulence in blue
gourami.
MATERIALS AND METHODS
Bacterial strains and cell cultures. The bacterial strains and plasmids used in
the present study are described in Table 1. E. tarda strains were grown in tryptic
soy broth (TSB; BD Biosciences) or Dulbecco modified Eagle medium (DMEM;
Invitrogen) at 25°C, while Escherichia coli strains were cultured in Luria-Bertani
broth (LB; BD Biosciences) at 37°C. Cultivation of bacteria in DMEM was
carried out under a 5% (vol/vol) CO2 atmosphere. When required, the medium
was supplemented with appropriate antibiotics at the following concentrations:
ampicillin, 100 g/ml; colistin, 12.5 g/ml; gentamicin, 100 g/ml; tetracycline, 15
g/ml; kanamycin, 50 g/ml. For the induction of T3SS proteins, E. tarda
PPD130/91 was grown in DMEM at 25°C, 35°C, or 37°C. Extracellular proteins
(ECP) were prepared from E. tarda cultures according to the protocol estab-
lished previously (54). HEK293A and HeLa cells were grown at 37°C in DMEM
supplemented with 10% heat-inactivated fetal bovine serum (FBS) under a 5%
(vol/vol) CO2 atmosphere.
Construction of deletion mutants, complementation, and plasmids. Nonpolar
esaN, eseG, and escB deletion mutants were generated by sacB-based allelic
exchange (13) as described previously (56). For example, two PCR fragments
were generated from PPD130/91 genomic DNA for the construction of the
eseG mutant. Primer pairs eseG-for plus eseG-int-rev and eseG-int-for plus
eseG-rev were used. The resulting products were a 633-bp fragment containing
the upstream region of eseG and a 690-bp fragment containing the downstream
region of eseG. A 16-bp overlap in the sequences permitted the amplification of
a 1,323-bp product during a second PCR with primers eseG-for and eseG-rev,
TABLE 1. List of strains and plasmids
Strain or plasmid Description and/or genotypea Reference or source
Strains
E. tarda
PPD130/91 Wild type; Kms Colr Amps; LD50 of 10
5.0 26
esaN PPD130/91 with in-frame deletion of esaN This study
eseG PPD130/91 with in-frame deletion of eseG This study
escB PPD130/91 with in-frame deletion of escB This study
escB/escB escB with pACYC-escB This study
eseG/eseG eseG with pACYC-eseG This study
esaN/esaN esaN with pACYC-esaN This study
E. coli
DH5  complementation Stratagene
MC1061 pir (pir) thi thr-1 leu6 proA2 his-4 argE2 lacY1 galK2 ara14 xyl5 supE44 pir 39
S17-1 pir RK2 tra regulon, pir, host for pir-dependent plasmids 42
BL21(DE3) E. coli B F ompT hsdS(rB mB) dcm Tetr gal (DE3) endA Hte Novagen
Plasmids
pGEM-Teasy Ampr Promega
pACYC184 Tetr Cmr Amersham
pACYC-escB pACYC184 with wild-type escB This study
pACYC-eseG pACYC184 with wild-type eseG This study
pACYC-esaN pACYC184 with wild-type esaN This study
pCX341 pBR322 derivative, used to fuse EseG to TEM-1 -lactamase 6
pCX-eseG eseG fused to TEM-1 This study
pRE112 pGP704 suicide plasmid, pir dependent; Cmr oriT oriV sacB 13
pRE-esaN pRE112 containing esaN fragment with aa 21 to 421 deleted This study
pRE-eseG pRE112 containing eseG fragment with aa 47 to 335 deleted This study
pRE-escB pRE112 containing escB fragment with aa 2 to 109 deleted This study
pEGFP-N1 Kmr BD Biosciences Clontech
pEGFP-eseG1–88 pEGFP-N1 with eseG encoding aa 1–88 This study
pEGFP-eseG89–339 pEGFP-N1 with eseG encoding aa 89–339 This study
pEGFP-eseG pEGFP-N1 with full-length eseG This study
pCDNA-3.1 CMV promoter; Ampr Neor Invitrogen
pCDNA-2HA-eseG pCDNA3.1 with 2HA tag at the N terminus of EseG This study
pCDNA-eseG pCDNA3.1 with full-length eseG This study
pCDNA-eseG89–339 pCDNA3.1 with eseG encoding aa 89–339 This study
pCDNA-eseG89–339, 142–192 pCDNA3.1 with eseG encoding aa 89–141 and 193–339 This study
a Km, kanamycin; Col, colistin; Amp, ampicillin; Cm, chloramphenicol; Tet, tetracycline; CMV, cytomegalovirus. Superscripts: r, resistance; s, sensitivity.
5012 XIE ET AL. INFECT. IMMUN.
each of which introduced a KpnI restriction enzyme site. The resulting PCR
product, containing a deletion from amino acid (aa) 47 to aa 335 of EseG, was
ligated into the suicide vector pRE112 (13) and transformed into E. coli SM10
pir. Single-crossover mutants were obtained by conjugal transfer of the resulting
plasmid into E. tarda PPD130/91. Deletion mutants were screened on 10%
sucrose–tryptic soy agar (TSA) plates. Mutants were verified by PCR, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western
blot analysis. No mutants showed growth defects when cultured in TSB or
DMEM. All primers used for the construction of mutants are listed in Table 2.
Site-directed mutagenesis of eseG was performed using overlap extension PCR
(17). For complementation of the escB mutant, the low-copy-number plasmid
pACYC184 was used, and the wild-type gene was inserted into the EcoRI and
ScaI sites of a chloramphenicol gene. The recombinant plasmid was screened by
tetracycline and was transferred into PPD130/91. The primers used are listed in
Table 2 as eseG-com-for, eseG-com-rev, escB-com-for, escB-com-rev, esaN-
com-for, and esaN-com-rev.
Secretion of EseG. To examine the secretion of EseG, overnight cultures of the
E. tarda wild-type strain PPD130/91, the esaN and eseG mutants, and the
eseG/eseG and esaN/esaN complemented strains were diluted 1:200 in DMEM
with 5 g/ml tetracycline. Bacteria were then grown without shaking for 20 h at
25°C under 5% CO2. Each bacterial culture was centrifuged. The supernatant
(labeled as ECP) was filtered (pore size, 0.22 m; Millipore) and was then
concentrated by an Amicon Ultra-15 centrifugal filtration device with a 10,000-
molecular-weight cutoff filter (Millipore). The bacterial pellet was resuspended
in 200 l phosphate-buffered saline (PBS), sonicated, and then centrifuged. The
supernatant was labeled as total bacterial proteins (TBP). One hundred fifty
micrograms of each TBP, or 6.0 g of each ECP, was boiled for 5 min in the SDS
sample buffer before each protein mixture was subjected to denaturing PAGE on
a NuPAGE 4 to 12% gradient gel (Invitrogen). Antigen-antibody complexes
were visualized with the SuperSignal West Pico chemiluminescent substrate
(Pierce), followed by exposure on Lumi-Film chemiluminescent detection film
(Roche). Proteins were separated by PAGE and transferred to a nitrocellulose
membrane. The membrane was cut into two parts; the upper part was probed
with a mouse anti-DnaK monoclonal antibody (Stressgen) at 1:2,000 and horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG at 1:5,000 (Sigma),
and the lower part was probed with a rabbit anti-EseG antibody (monopeptide
antibodies were raised in rabbits against keyhole limpet hemocyanin-conjugated
peptides of EseG [EseG aa 93 to 106; DQLRAQAQEAEQKA] by BioGenes
[Berlin, Germany]) diluted at 1:2,000 and HRP-conjugated goat anti-rabbit IgG
at 1:3,000 (Santa Cruz).
Fluorescence microscopy for observation of EseG translocation. HeLa cells
were seeded into wells of a 24-well plate (with coverslips at the bottom) at 1 
105 cells per well in DMEM for 18 h at 35°C in a 5% CO2 incubator. Wild-type
PPD130/91, the esaN mutant with pCX-eseG, and PPD130/91 with pCX341
were inoculated into TSB, supplemented with tetracycline, and grown at 35°C
without shaking the night before infection. HeLa cells were washed twice with
PBS, and bacteria were applied to HeLa cells at a multiplicity of infection (MOI)
of 100 in DMEM without serum. Three hours later, HeLa cell monolayers were
washed twice with PBS. The infection then proceeded for another 5 h in DMEM.
Pictures were taken under a Zeiss Axiovert inverted microscope by using a Zeiss
AxioCam MRc digital camera.
Fractionation of infected HeLa cells. Infected HeLa cells were fractionated as
described by Coombes et al. (9) with minor modifications. Briefly, HeLa cells
were seeded at 5  106 per 100-mm-diameter culture dish 1 day before the
infection. Before infection, overnight E. tarda cultures were diluted 1:20 into
fresh TSB, grown for 3 h without shaking, and then applied to HeLa cells at an
MOI of 100 in DMEM. Culture dishes were maintained at 35°C in a 5% CO2
incubator for 3 h. The culture dishes were then washed 3 times with prewarmed
PBS, and the medium was replaced with prewarmed DMEM with 5% FBS and
30 g/ml gentamicin. Infections were allowed to proceed for another 5 h before
harvest and resuspension in 300 l homogenization buffer (HB) (250 mM su-
crose, 3 mM imidazole, 0.5 mM EDTA [pH 7.4]). The cells were homogenized
by mechanical lysis using a 1-ml syringe with a 22-gauge needle. The lysate was
spun at 3,000  g for 15 min at 4°C, and the supernatant was transferred to a
small plastic ultracentrifuge tube and spun at 41,000  g in an ultracentrifuge
(Beckman) for 30 min at 4°C. The supernatant (cytosolic fraction) was mixed
with 60 l 5 SDS sample buffer containing 5% -mercaptoethanol. The pellet
(membrane fraction) was resuspended in a mixture of 240 l HB and 60 l 5
SDS sample buffer containing 5% -mercaptoethanol and was boiled for 5 min.
Fractions (40 l) were transferred to a polyvinylidene difluoride (PVDF) mem-
brane for Western blot analysis. The membrane was probed with the rabbit
anti-EseG antiserum at 1:2,000 and with a polyclonal anti-EvpP antiserum (54)
at 1:3,000. The membrane was stripped with 8.0 M guanidine hydrochloride and
10 mM dithiothreitol and was reprobed with a monoclonal anti--tubulin anti-
TABLE 2. Oligonucleotides used in this study
Designation Nucleotide sequence
esaN-for ...........................................................................................ATGGTACC GTTCATAGGCTGTCTCCACGGT
esaN-int-rev .....................................................................................TCCCACCCTGCCGTCG CCGCTGAGCGCCACCCTCA
esaN-int-for .....................................................................................CGACGGCAGGGTGGGACAGTCGA
esaN-rev...........................................................................................ATGGTACC AGATTCTGATCCAGCCAGATA
esaN-com-for...................................................................................AGAATTCGAACGCGAGCTGTTCACCAC
esaN-com-rev ..................................................................................AAGTACTGCGTAGCTGCGTCAGCAT
eseG-for ...........................................................................................ATGGTACC TGGCTGGAGACGAAGAAGGG
eseG-int-rev.....................................................................................GATGATCAACGGCGTTTACAGCTTTGCCTGACC
eseG-int-for .....................................................................................AACGCCGTTGATCATCATAGGCTC
eseG-rev...........................................................................................ATGGTACCCGCTATTGCTGCCGCTAACC
eseG-com-for ..................................................................................AGAATTCGCAGCAGCAGCAGGAGTAT
eseG-com-rev ..................................................................................AAGTACTGTATGGGAGGAGGGGGTCA
escB-for............................................................................................AAGGTACCAAAGACTTTCAGGCCAAGCAGG
escB-int-rev......................................................................................GCACTCCGCCATGTGAAACATGGGGGTCTCCAAATGATATGATATATT
escB-int-for......................................................................................TTTCACATGGCGGAGTGCCTGCT
escB-rev ...........................................................................................TTGGTACCCAGGGTGAGCACTTTGGCGAC
escB-com-for ...................................................................................AAGAATTCATTAAAGAGGAGAAATTAACCATGACGTCCGCACCGCTCT
escB-com-rev...................................................................................AAAGTACTTATTAGGGTTGATTAAGCGTA
pEGFP-eseGF ................................................................................AAAAGCTTATGCCTTGGATGCCACGAT
pEGFP-eseGR................................................................................AAGGATCCGCAAAGCTGTAGCGTCGCG
pEGFP-eseG88R............................................................................AAGGATCCGCCCCCGGCGCTCGGCTGCG
pEGFP-eseG89F ............................................................................AAAAGCTTATGTCAGCGCCCCTGGACCAGC
escB-For...........................................................................................AAGGATCCATGACGTCCGCACCGCTCT
escB-Rev..........................................................................................TTAAGCTTGGGTTGATTAAGCGTATCCAG
pCDNA-2HA-eseG-For ................................................................AAGCCCGGGCAATGCCTTGGATGCCACGAT
pCDNA-eseG-For ..........................................................................AAAAGCTTGCCACCATGGCACCTTGGATGCCACGATTGCG
pCDNA-eseG-Rev-stop.................................................................AAGGATCCTCAGGCAAAGCTGTAGCGTCG
pCDNA-eseG89-For ......................................................................AAGAATTCGCCACCATGGCATCAGCGCCCCTGGACCAGC
pCDNA-eseG142-int-Rev ...............................................................GAGCCCGGTGATCAGTGCGGC
pCDNA-eseG193-int-for.................................................................GCCGCACTGATCACCGGGCTCTGGCTGGGAAAAGTCAGCG
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body (Sigma) at 1:2,000 and a monoclonal anti-calnexin antibody (Stressgen) at
1:2,000.
Virulence in blue gourami. Healthy naïve blue gourami (Trichogaster
trichopterus [Pallas]) were infected with E. tarda as described previously by Ling
et al. (26). Fish mortalities were recorded over a period of 7 days after intra-
muscular injections near the dorsal fins. The LD50s were calculated by the
method of Reed and Muench (37). For each strain, the LD50 estimation was
performed at least three times.
Transfection of HEK293A cells and immunofluorescence microscopy.
HEK293A cells were seeded on glass coverslips in 6-well tissue culture plates for
24 h before transfection at a density of 3  105 cells/well. Cells were transiently
transfected with 6 l Fugene 6 (Roche) using 2.0 g DNA optimized according
to the manufacturer’s instructions. Cells were subsequently incubated at 37°C
under 5% CO2 for 18 h prior to fixation and antibody staining. For staining,
transfected cells were fixed with 4% paraformaldehyde in PBS, permeabilized
with 0.1% Triton X-100 in PBS, and stained as described by Abrahams and
coworkers (1). Antibodies were used at the following dilutions: mouse monoclo-
nal anti--tubulin antibody (Sigma), 1:5,000; rabbit anti-EseG antiserum, 1:300;
goat anti-mouse IgG (Alexa 594; Molecular Probes), 1:200; and goat anti-rabbit
IgG (Alexa 488; Molecular Probes), 1:200. For the quantification of microtubule
destabilization, 120 positively transfected cells were scored for the disappearance
of microtubule structure in at least three independent experiments.
Immunoprecipitation (IP) and Western blot analysis. HEK293A cells were
grown in 100-mm-diameter culture dishes transfected with 24 g pCDNA-EseG
by using 20 l Lipofectamine 2000 reagent (Invitrogen). After 20 h, cells were
washed with cold PBS and were scraped. Cells were then washed three times with
cold PBS and were lysed for 30 min with a modified radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 10%
glycerol, 50 mM NaF, 0.4 mM EDTA, 10 mM sodium pyrophosphate) containing
protease inhibitors (Complete; Roche). Homogenates were centrifuged, and
supernatants were incubated overnight at 4°C, with gentle rotation, with IgG(	)
or an anti--tubulin antibody bound to protein A-agarose (Invitrogen). After
incubation, immunoprecipitates were washed extensively with ice-cold modified
RIPA buffer. Proteins bound to the agarose were eluted by heating at 95°C for
4 min in SDS-PAGE sample buffer. Eluted proteins were separated by SDS-
PAGE, transferred to a nitrocellulose membrane, and probed with IgG(	) or an
anti--tubulin antibody, followed by detection by chemiluminescence. A mouse
monoclonal antibody against green fluorescent protein (GFP) (Molecular
Probes), a mouse monoclonal anti--tubulin antibody (Sigma), and mouse
IgG(	) (Sigma), all at 1:2,000, were used.
Quantitative 2HA-EseG immunoprecipitation and mass spectrometry. Bind-
ing partners for EseG were identified exactly as described previously for SopB
(38). Briefly, unlabeled HEK293 cells were transfected with EseG tagged with 2
hemagglutinin molecules (2HA-EseG) for 24 h and were then mixed with an
equal number of nontransfected cells labeled with 13C6-Arg and 2H4-Lys. EseG
was immunoprecipitated and prepared for mass spectrometry as described pre-
viously (38). Digested immunoprecipitates were analyzed with an LTQ Orbitrap
XL system (5). The protein was identified, and quantitative ratios were calcu-
lated, exactly as described previously (38).
Pulldown assay and Western blotting. EscB-His6 was purified according to a
batch purification protocol (Qiagen). E. tarda with pCX-eseG and E. tarda with
pCX341 were subcultured separately into DMEM and were induced with 0.4
mM isopropyl--D-thiogalactopyranoside (IPTG) for 5 h before harvesting. Cell
pellets were sonicated and then centrifuged to collect supernatants. His-tagged
EscB beads were then incubated with cell lysates for 2 h at 4°C with gentle
rotation. Beads were washed with the washing buffer 7 times, and proteins bound
to beads were resolved by a NuPAGE 4 to 12% Bis-Tris gel (Invitrogen).
Proteins were transferred to a PVDF membrane and were probed with a mouse
anti--lactamase antibody at 1:2,000 (QED Bioscience Inc.) and with HRP-
conjugated goat anti-mouse IgG at 1:5,000 (Sigma).
Statistical analysis. All data are presented as means 
 standard deviations
(SD). Comparisons between groups were tested by one-way analysis of variance
(ANOVA), and the least significant difference (LSD) was used for multiple
comparisons.
RESULTS
Sequence analysis of EseG. EseG is a 339-amino-acid
protein encoded inside the E. tarda T3SS gene cluster (45).
It possesses nine positive charges (http://ihg2.helmholtz
-muenchen.de/ihg/mitoprot.html) (7) and is classified as an
unstable protein according to the instability index calculated
by a computer model (http://www.expasy.org/tools/protparam
.html). Amino acid sequence comparison shows that EseG is
very similar to a hypothetical protein from Edwardsiella ictaluri
(ABC60070) (70% identity and 79% similarity). It also shows
homology to hypothetical proteins from other bacteria, such as
ABN61461 of Shewanella baltica OS155 (24.4% identity and
45.9% similarity) and ZP04613838 of Yersinia rohdei ATCC
43380 (22.9% identity and 41.9% similarity). Interestingly,
EseG also shares homology with SseF (CAA12191) and SseG
(CAA12192), effector proteins secreted by a T3SS of Salmo-
nella enterica serovar Typhimurium (12, 23, 24), suggesting that
EseG may also function as an effector protein of the T3SS in E.
tarda. In addition, EseG and its homologs, especially SseF and
SseG, share a conserved region (Fig. 1), which is used by SseF
to recruit dynein to the SCV (1) and by SseG to target the
Golgi complex and to allow Salmonella to multiply vigorously
(40). We used this information to examine a possible function
of this conserved fragment in EseG.
EseG is secreted in a T3SS-dependent manner. The E. tarda
wild-type strain PPD130/91, a T3SS-deficient esaN mutant, a
eseG mutant, and two complemented strains (the esaN/esaN
and eseG/eseG strains) were examined for the secretion of
EseG. escN, a homolog of esaN in E. coli, is an ATPase that
energizes the transportation of T3SS effectors and translocon
components. Mutation in escN has been shown to abolish the
secretion or translocation of T3SS substrates (2). Equal
amounts of extracellular proteins (ECP) and total bacterial
proteins (TBP) from these E. tarda strains were collected sep-
arately and subjected to Western blot analyses using anti-EseG
and anti-DnaK antibodies. In TBP fractions, EseG was de-
tected only in the complemented eseG mutant (Fig. 2). How-
ever, in ECP fractions, EseG was detected in the wild type and
in complemented esaN and eseG mutants. EseG was not
detected in the bacterial pellets of the wild type or the com-
plemented esaN mutant. A possible explanation may be that
EseG was rapidly secreted once it was synthesized by the chro-
mosome. Thus, EseG was detected in a bacterial pellet only
when the mutant was complemented with eseG in the low-
copy-number plasmid pACYC184. DnaK was not detected in
any ECP, showing that detection of EseG is not due to leakage
from bacterial pellets. These results indicate that the secretion
of EseG is dependent on a functional T3SS.
EseG is translocated into HeLa cells at 35°C and is localized
in the host cell membrane. Effector translocation was detected
directly in live host cells (mammalian cells) by using the fluo-
FIG. 1. Amino acid sequence alignment of a conserved region in E.
tarda EseG (AAX76916) and its homologs Salmonella serovar Typhi-
murium SseF and SseG (CAA12191 and CAA12192, respectively) and
hypothetical proteins of E. ictaluri (ABC60070), S. baltica OS155
(ABN61461), and Yersinia intermedia ATCC 29909 (ZP00833567). As-
terisks denote identical residues; colons, conserved substitutions; pe-
riods, similar amino acids. Boldface indicates residues of EseG that are
identical in all sequences compared.
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rescent -lactamase substrate CCF2-AM (6, 25). When
CCF2-AM permeates host cells, it exhibits fluorescence reso-
nance energy transfer (FRET), resulting in a green fluores-
cence signal. Cleavage of the substrate by an effector--lacta-
mase molecule disrupts FRET, resulting in a shift to a blue
fluorescence signal (6). Considering that E. tarda is also a
human pathogen (19) and that the secretion of EseG de-
creased drastically at 37°C (Fig. 3A), we chose to culture E.
tarda, and infect HeLa cells, at 35°C, the condition under
which EseG was maintained at a high level (Fig. 3A). Under a
fluorescence microscope, most HeLa cells appeared blue, in-
dicating that the translocation of EseG-TEM into these cells
had taken place (Fig. 3B, left). In contrast, almost all HeLa
cells infected with E. tarda expressing pCX341 (empty vector)
appeared green (Fig. 3B, right). Taken together, our results
suggested that EseG is a T3SS effector.
To localize EseG in infected host cells, HeLa cells were
infected with the E. tarda wild-type strain PPD130/91 and were
subjected to subcellular fractionation. Calnexin and -tubulin
were used as subcellular markers of membrane and cytosolic
proteins, respectively, in HeLa cells. EvpP, a T6SS-dependent
secreted protein (54), was found in the E. tarda pellet (TCP)
and E. tarda ECP but not in the infected HeLa cell cytosolic
or membrane fraction (Fig. 3C), indicating that these frac-
tions were not contaminated by the bacteria. Our data
showed that EseG is localized in the HeLa cell membrane
fraction (Fig. 3C).
Role of EseG in E. tarda pathogenesis. To characterize fur-
ther the effects of eseG and esaN on the virulence of E. tarda,
we determined the LD50s of nonpolar deletion mutants devoid
of eseG or esaN in vivo (Table 3). In this study, LD50 refers to
the minimum lethal dose of E. tarda required to kill half of the
blue gourami tested within 7 days. The esaN mutant was
modestly attenuated—its LD50 was about 1 log unit higher
FIG. 2. EseG is secreted into the culture supernatant in a T3SS-
dependent manner. Western blot analysis of EseG was conducted with
bacterial pellets (TBP) and culture supernatants (ECP) from identical
numbers of organisms of wild-type E. tarda PPD130/91, its esaN and
eseG mutants, and the eseG/eseG and esaN/esaN complemented
strains. The Western blot was probed with anti-EseG and an antibody
against DnaK, a bacterial cytosolic marker. EseG was not detected in
the ECP of the esaN or eseG background, and DnaK was not
detected in any ECP, showing that detection of EseG is not due to
leakage from bacterial pellets. The asterisk indicates the nonspecific
band detected in the bacterial pellet.
FIG. 3. EseG is translocated into the cytosol of the host cell and is localized in its membrane fraction. (A) EseG is secreted in a temperature-
dependent manner. ECP were prepared from identical amounts of the wild-type E. tarda strain PPD130/91 cultured in DMEM at 25°C, 35°C, or
37°C and were then probed with anti-EseG for Western blot analysis. (B) Demonstration of the translocation of the E tarda effector EseG into
live HeLa cells using TEM-1 fusions and fluorescence microscopy. HeLa cells were infected with wild-type E. tarda strains expressing EseG-TEM
(left) or TEM-1 only (right). Eight hours after infection, HeLa cells were washed and loaded with CCF2-AM. Translocation of the effector-TEM
into host cells causes the cleavage of the CCF2-AM product, resulting in the emission of a blue fluorescence signal. Uncleaved CCF2 emits green
fluorescence. Bars, 200 M. (C) EseG is localized at the HeLa membrane fraction. HeLa cells were infected with wild-type E. tarda PPD130/91
and were subjected to subcellular fractionation by differential centrifugation. Fractions were analyzed by Western blot analyses using anti-EseG,
anti-EvpP, anti--tubulin, and anti-calnexin antibodies.
TABLE 3. Characterization of wild-type E. tarda PPD130/91
and its mutants
Strain Length of WT
a
protein (aa)
Codons
deleted (aa) LD50 P
b
PPD130/91 104.91 
 0.15 NA
esaN mutant 438 21–421 105.94 
 0.19 0.001
eseG mutant 339 47–335 105.01 
 0.10 0.05
escB mutant 163 2–109 NDc ND
a WT, wild type.
b Obtained using one-way ANOVA and LSD. All P values refer to the wild-
type LD50 (n, 3). NA, not applicable.
c ND, not determined.
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than that of the wild type, and the difference was statistically
significant (Table 3). In contrast, the eseG mutant showed
only slight attenuation, with an LD50 about 0.17 to 0.35 log unit
higher than that of the wild type, and the difference was not
statistically significant (Table 3).
EscB is the chaperone of EseG and is involved in the stabi-
lization of EseG. The escB gene is located upstream of eseG
and is transcribed in the same direction as eseG in the E. tarda
PPD130/91 T3SS gene cluster (45). The start codon of EseG
overlaps with EscB. EscB is small (18 kDa) and acidic (pI
4.64), characteristics common to most chaperones (10). Fur-
thermore, it has a tetratricopeptide repeat domain, as identi-
fied by a Pfam scan (http://pfam.janelia.org/). This domain is
also present in the LcrH/SycD-like chaperone (35). To test
whether EscB is required for the secretion of EseG, E. tarda
ECP were harvested from equal numbers of organisms of the
wild type, the esaN and escB mutants, and the escB/escB
complemented strain and were probed with anti-EseG and
anti-DnaK antibodies. As shown in Fig. 4A, EseG was not
detected in the ECP of the escB or esaN mutant; however,
it was detected in the ECP when the escB mutant was com-
plemented with the low-copy-number plasmid pACYC-escB.
Thus, EsaN and EscB are required for the secretion of EseG.
Chaperone proteins usually bind to their cognate substrate
directly (47, 49, 55). Since EscB likely functions as a chaperone
of EseG, we performed in vitro binding assays to test whether
EscB binds to EseG directly. His-tagged EscB was expressed
and purified to pull down cell lysates of E. tarda PPD130/91
harboring pCX-eseG (WT/pCX-eseG) or pCX341 (WT/pCX-
341). Under IPTG induction conditions, WT/pCX-eseG and
WT/pCX-341 expressed EseG-TEM and TEM, respectively
(Fig. 4B). Our results showed that EscB could pull down EseG-
TEM but not TEM (Fig. 4C), suggesting that EscB and EseG
interact with each other in the cytosol of E. tarda.
EseG interacts with -tubulin. In order to investigate host
interaction partners of EseG, two approaches were used. First,
SILAC (stable isotope labeling with amino acids in cell cul-
ture)-based quantitative proteomics, as previously used to
identify host targets of the Salmonella type III effector protein
SopB (38), was used to analyze immunoprecipitates of
pCDNA3.1-2HA-EseG-transfected cells (expressing HA-
tagged EseG) versus nontransfected cells (Fig. 5A). Second,
immunoprecipitation of cell lysates prepared from pEGFP-N1-
or pEGFP-eseG-transfected 293A cells, followed by mass spec-
trometric analysis of additional bands obtained from EseG,
was performed (data not shown). The SILAC result identified
at least eight peptides from tubulin, all showing the same
pattern. Together, these two approaches identified -tubulin,
-tubulin, and dynein as possible interaction partners of EseG.
The interactions between EseG and -tubulin were further
confirmed by IP using a monoclonal anti--tubulin antibody
(Fig. 5B, right). IgG(	) was used as a negative control for the
IP experiment to show that it did not pull down -tubulin (Fig.
5B, left).
The N-terminal fragment of EseG containing 88 amino acid
residues is important for its interaction with -tubulin. To
identify the region(s) of EseG that interacts with -tubulin, a
series of truncated EseG proteins fused at the N terminus of
GFP were constructed and overexpressed in HEK293A cells by
transfection. These included EseG-GFP, EseG1–88-GFP,
EseG89–339-GFP (251 residues of the C-terminal end), and
GFP alone (negative control). As shown in Fig. 6, GFP was
detected in all cell lysates, with molecular weights consistent
with the predicted sizes of fusion proteins representing the
respective constructs. Multiple bands were detected for
EseG1–88-GFP, possibly due to the unstable nature of the N-
terminal end of EseG. EseG1–88-GFP and EseG-GFP could be
pulled down by the anti--tubulin antibody (Fig. 6B). These
results suggested that the N-terminal fragment of EseG con-
sisting of 88 amino acid residues is necessary for its interaction
with -tubulin.
Functional dissection of EseG. Subcellular fractionation re-
vealed the presence of translocated EseG in the membrane
fractions of host cells (Fig. 3C). Sequence analyses of EseG
found three hydrophobic regions that may act as transmem-
brane domains (Fig. 7A). In addition, the N-terminal region is
rich in proline residues, with 14 prolines in the first 88 residues
(Fig. 7A). The conserved fragment (EseG142–192) that has sim-
ilarity with Salmonella effectors SseF and SseG covered part of
the CH2 region (the second transmembrane domain). To gain
further insight into the potential functions of these domains, a
series of GFP-tagged (constructs in pEGFP-N1) and non-
tagged (pCDNA-3.1) EseG constructs were prepared. Im-
munoprecipitation analyses revealed that all truncated EseG
constructs that contained the 88-aa N-terminal fragment inter-
acted with -tubulin (Fig. 6 and 7). Immunofluorescence of
nontagged truncated EseG showed that the conserved motif
FIG. 4. EscB is the chaperone of EseG. (A) EseG was not secreted
in the absence of EscB, and its secretion was restored by EscB trans-
complementation. ECP from equal amounts of E. tarda PPD130/91,
esaN, escB, and escB/escB organisms were probed with anti-EseG
and anti-DnaK antibodies. The asterisk indicates the nonspecific band
detected in the bacterial pellet. (B) EscB interacts with EseG-TEM.
His-tagged EscB beads were used to immunoprecipitate identical
amounts of cell lysates prepared from E. tarda PPD130/91/pCX-341
and PPD130/91/pCX-eseG. Proteins pulled down by the His-tagged
EscB were separated by SDS-PAGE and subjected to Western blot
analysis with anti-His and anti--lactamase antibodies.
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EseG142–192 (Fig. 1) was involved in the microtubule destabi-
lization activity of EseG (Fig. 7).
EseG disassembles microtubules in vivo. To investigate
whether EseG is colocalized with -tubulin, several truncated
versions of EseG without tags were constructed in the
pCDNA3.1 vector and were expressed in HEK293A cells,
namely, pCDNA-eseG, pCDNA-eseG89–339, pCDNA-eseG89–339,
142–192, and empty vectors (Fig. 7C). HEK 293A cells were
then stained with anti-EseG (green) and anti--tubulin (red)
antibodies. As shown in Fig. 7C, HEK293A cells transfected
with full-length EseG, or with EseG89–339, showed destabiliza-
tion of microtubule structures. In contrast, HEK293A cells
transfected with an empty vector showed normal filamentous
microtubules that could be stained by the anti--tubulin anti-
body. Similar phenotypes were observed in both HeLa and
Cos-7 cells (data not shown). Interestingly, removal of the
conserved fragment (residues 142 to 192) resulted in a com-
plete loss of microtubule destabilization activity. EseG89–339,
142–192, which did not contain the conserved domain, was,
instead, redistributed in a punctate form, mainly around the
nucleus (Fig. 7C).
The level of microtubule destabilization was then measured
in HEK293A cells after transfection with different truncated
versions of EseG. The percentages of transfected cells that
showed microtubule destabilization are presented in Fig. 7D.
Expression of EseG in HEK293A cells caused 58.3% of trans-
FIG. 5. EseG interacts with -tubulin. (A) SILAC 2HA-EseG immunoprecipitations. Anti-HA was used to immunoprecipitate cell lysates from
nontransfected cells (stable isotope-labeled cells) and HA-EseG-overexpressing cells (unlabeled cells). A peptide from -tubulin (left) is present
predominantly in the unlabeled, specific form (open arrowhead), while a peptide from LETM1 and EF-hand domain-containing protein 1 (right)
is present in roughly equal amounts in the unlabeled (open arrowhead) and labeled (filled arrowhead) forms. The SILAC result showed that more
than eight peptides, all showing the same pattern, were identified from tubulin. (B) EseG interacts with -tubulin. HEK293A cells were transfected
with either pEGFP-N1 or pEGFP-EseG, followed by solubilization to produce cell lysates. These cell lysates were immunoprecipitated (IP) with
IgG(	) (as a control) (left) or with an anti--tubulin antibody (right). EseG-GFP fusion proteins were detected by an anti-GFP antibody
(immunoblotting [IB]). The doublet background bands are likely heavy chains of IgG produced by IP.
FIG. 6. N-terminal residues (aa 1 to 88) of EseG are important for
interaction with -tubulin. (A) HEK293A cells were transfected with
pEGFP-N, pEGFP-EseG, pEGFP-EseG1–88, or pEGFP-EseG89–339,
followed by solubilization to produce cell lysates. EseG-GFP fusion
proteins exhibited different molecular sizes (indicated by arrows), de-
pending on the size of each construct (upper panel). -Tubulin was
used as a loading control (lower panel). (B) EseG was immunopre-
cipitated (IP) with an anti--tubulin antibody. GFP fusion proteins
were detected by an anti-GFP antibody (upper panel), and -tubulin
was used as a loading control (lower panel). EseG1–88-GFP and EseG-
GFP were pulled down by the anti--tubulin antibody (indicated by
arrows).
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fected cells to show destabilized microtubules, whereas the
removal of an 88-residue N-terminal fragment (pCDNA-
eseG89–339) resulted in 90.5% of transfected cells exhibiting
microtubule destabilization. Most importantly, deletion of res-
idues 142 to 192 (pCDNA-eseG89–339, 142–192) resulted in a
total loss of microtubule destabilization; the rate of microtu-
bule destabilization dropped to a level (1.67%) approximately
the same as that of the vector control (Fig. 7D). These results
suggest that the conserved domain of EseG (amino acid resi-
dues 142 to 192) is required to destabilize microtubule net-
works.
DISCUSSION
E. tarda belongs to the family Enterobacteriaceae and is
closely related to other enteric pathogens, such as pathogenic
Escherichia coli strains and pathogenic Yersinia and Salmonella
species. These enteric pathogens and pathogenic E. tarda
strains can cause many diseases in humans, such as typhoid
fever, diarrheal diseases, and bubonic plague. One of the vir-
ulence factors shared by these pathogens is the T3SS. The
study of T3SS effectors in E. tarda will help us to understand
not only the infection pathway of this pathogen but also the
general pathogenic features of these effectors in enteric dis-
eases. To dissect the pathogenicity of E. tarda, the previously
established fish infection model, blue gourami, was used (26).
This model helps us to identify the important virulence factors
of E. tarda by comparing the LD50s of various mutants with
that of the wild type. For example, when one of the two T3SS-
regulatory genes, esrB and esrC, was deleted in E. tarda
PPD130/91, the LD50s of the resulting mutants were 3 log units
higher than that of the wild type (43, 56). Although it has been
speculated that Edwardsiella effectors may be responsible for
the intracellular growth of the bacteria in HEp-2 cells (34) and
for their multiplication in murine and fish macrophages (33,
45), no T3SS effectors of E. tarda have been identified yet. In
this study, we have identified the first effector of E. tarda,
EseG. The role of EseG in the pathogenesis of E. tarda was
further investigated in tissue culture models and in fish.
Establishing a protocol for studying the translocation of E.
tarda T3SS effectors into host cells. TEM-1 -lactamase was
developed as a fluorescence-based reporter to directly identify
effectors that are translocated into mammalian host cells by
extracellular pathogens (6, 25). Previously, it has been shown
that E. tarda is an intracellular pathogen, capable of penetrat-
ing and replicating inside cultured HEp-2 cells, HeLa cells, and
murine macrophages (19, 27, 33, 34). In this study, we modified
the TEM-based system to identify a T3SS effector (EseG) from
E. tarda.
Wild-type E. tarda PPD130/91 is a fish isolate whose T3SS is
functionally active at lower temperatures, such as 25°C, but not
at a higher temperatures, such as 37°C (44). To study the
translocation of EseG into host cells, we initially cultured E.
tarda expressing a EseG-TEM fusion protein at 25°C and used
these bacteria to infect a fish cell line, epithelioma papillosum
of carp. All cells infected with E. tarda appeared green (data
not shown), suggesting that either EseG-TEM was not trans-
located into cells of epithelioma papillosum of carp or the
catalytic activity of TEM was inhibited in epithelioma papillo-
sum of carp cells at 25°C. To circumvent the limitation caused
by these possibilities, HeLa cells were chosen for TEM exper-
iments. We grew E. tarda and HeLa cells at 35°C, a condition
under which the T3SS of E. tarda was functionally active (Fig.
3A). Also, HeLa cell growth was not affected (4). As expected,
we observed the translocation of EseG-TEM into HeLa cells
8 h after infection. Thus, this modified TEM-based protocol
was shown to be suitable for the identification of effectors
secreted by the T3SS, and possibly the T6SS, of Edwardsiella.
Cellular functions of EseG. Full-length EseG was able to
destabilize microtubule structures when overexpressed in
HeLa cells (Fig. 7). This phenotype is reminiscent of those
caused by a group of T3SS effectors, such as enteropathogenic
E. coli (EPEC) effectors EspG and EspG2 and the Shigella
effector VirA (14, 28). EspG, EspG2, and VirA belong to
the EspG protein family (http://pfam.janelia.org/family?acc
PF06872). These three proteins share a striking homology at
the amino acid level (14, 28). VirA can affect the structure of
microtubule networks when transiently expressed in host cells,
and EspG and EspG2 trigger the destruction of microtubule
networks beneath adherent EPEC (28, 52). Either EspG or
EspG2 can rescue the invasive ability of a Shigella virA mutant,
indicating that these effector proteins are functionally equiva-
lent to those in Shigella (14). Like EspG family proteins, EseG
can also trigger microtubule rearrangement mediated by its
microtubule destabilization activity. Despite the fact that EseG
shows functional phenotypes similar to those of the EspG
family proteins, there is no amino acid homology between
them. It is possible that EseG has a microtubule-inhibitory
mechanism different from those of EspG, EspG2, and VirA.
Alternatively, EseG and the EspG family may share a similar
FIG. 7. Functional dissection of the E tarda T3SS effector EseG. (A) Sequence analysis of EseG. Hydrophobic regions CH1, CH2, and CH3
are underlined in blue, red, and green, respectively. Amino acid residues of the N-terminal region (residues 1 to 88) of EseG interacting with
-tubulin are underlined. Prolines in the N-terminal region are in boldface. The conserved fragment (EseG142–192) that has similarity with
Salmonella effectors SseF and SseG is shaded. (B) Schematic representation of truncated polypeptides derived from EseG. The ability of each
polypeptide to destabilize microtubules and to interact with -tubulin is indicated next to its schematic structure. Various truncations of
GFP-tagged EseG were constructed for the -tubulin interaction studies, whereas untagged truncated EseG proteins in pCDNA3.1 were used for
microtubule destabilization studies (panels C and D). ND, not determined. (C) The conserved hydrophobic segment in EseG is essential for
EseG-mediated phenotypes. HEK293A cells were transiently transfected with EseG, EseG89–339, EseG89–339, 142–192, or pCDNA3.1 with
pEGFP-N1 (empty-vector control). EseG and microtubules are labeled with an anti-EseG antibody (green) and an anti--tubulin antibody (red),
respectively. (D) Measurement of microtubule destabilization in HEK293A cells transfected with EseG, EseG89–339, EseG89–339, 142–192, or an
empty vector (negative control). One hundred twenty transfected cells were counted in at least three independent experiments. Data are presented
as means
 SD. Bars with three asterisks are significantly different from the EseG bar (P 0.001). P values were obtained using one-way ANOVA
and the least-significant-difference (LSD) method. All values refer to the wild type (n  3).
VOL. 78, 2010 EseG TRIGGERS MICROTUBULE DESTABILIZATION 5019
3-dimensional structural motif that determines their common
microtubule-inhibitory activity.
Mutations of either one of the homologs of eseG in Salmo-
nella (sseF and sseG) have been reported to render Salmonella
less able to replicate in epithelial cells (1, 40). SseF and SseG
help to maintain the SCV in a juxtanuclear, Golgi network-
associated localization, which is required for the intracellular
proliferation of Salmonella (1, 40). Furthermore, EseG, like
SseG and SseF, is localized to the host cell membrane fraction
(Fig. 3C) (1). Since EseG shares homology with SseF and SseG
(Fig. 1), it is likely that EseG may have a function similar to
that of SseF and SseG, i.e., to enhance the proliferation of E.
tarda in host cells. In future work, we will explore whether the
localization of the eseG mutant in host cells differs from that
of the wild type and whether eseG bacteria have a decreased
ability to replicate in host cells.
Further comparison of the amino acid sequences of EseG,
SseF, and SseG revealed a conserved domain in all three pro-
teins (Fig. 1), namely, EseG142–192, SseF85–135, and SseG90–133.
SseF85–135 is located in the second transmembrane domain of
SseF (residues 128 to 179), which is involved in the positioning
of intracellular Salmonella and the recruitment of dynein to
SCV (1). SseG90–133 is located in a Golgi complex-targeting
domain of SseG (residues 88 to 142) that allows Salmonella to
multiply near the Golgi network (40). EseG142–192 might be
required for EseG to destabilize microtubule structures, as
evidenced by the observation that the microtubule destabiliza-
tion ability of EseG dropped to the same level as that of the
negative control when EseG142–192 was deleted (Fig. 7). Fur-
thermore, since SseF and SseG share similarities with EseG in
this conserved domain, it will be interesting to determine
whether SseF and SseG can also destabilize microtubules using
this domain. Functional study of EseG may help to reveal
novel functions of SseF and SseG in Salmonella virulence.
EseG interacts with -tubulin. The first 88 N-terminal resi-
dues of EseG (EseG1–88) are important for this interaction
(Fig. 6 and 7). Two properties of EseG might account for this
interaction. First, these 88 N-terminal residues contain 14 pro-
line residues (Fig. 7A), which appear to be critical in protein-
protein interactions. It has been reported that several protein-
interacting domains prefer ligand sequences that are rich in
proline residues, for example, Src homology 3 (SH3) and WW
domains (21). Second, these 88 residues include 5 residues with
net positive charges, which are important for protein-protein
interactions. Considering that EseG destabilizes microtubule
structures through the conserved domain EseG142–192, while
the first 88 N-terminal residues of EseG are important for the
interaction between EseG and -tubulin (Fig. 6 and 7), we
speculate that EseG142–192 interacts with another protein, or
that it exhibits an unknown enzyme-like activity, to destabi-
lize microtubule structures. Alternatively, the deletions in
EseG142–192 may interfere with the proper cellular localization
of EseG, resulting in the loss of its microtubule destabilization
activity. However, we cannot rule out the possibility that the
disruption in the microtubule destabilization function of
EseG142–192 may arise from the effect of its improper folding.
The fact that the ability to bind -tubulin and the ability to
destabilize microtubule structures are not mediated by the
same domain (or enzyme-like activity) is not unique to EseG.
The Shigella effector VirA also interacts with - and -tubulin
heterodimers but induces microtubule destabilization through
an -tubulin-specific cysteine protease-like activity (51, 52, 53).
Interestingly, VirA is not a protease, nor does it directly sever
or destabilize microtubules (11, 15).
In conclusion, we have demonstrated the various cellular
activities of EseG, such as its interaction with -tubulin, de-
stabilization of microtubules, and contribution to the virulence
of E. tarda in vivo. Our ongoing work is to explore whether
there is any microtubule destabilization in infected HeLa cells
when EseG is translocated into the host cells at a high level and
to examine the cellular localization of the translocated EseG.
Since microtubules are also involved in initiating the process of
bacterial entry (22), intracellular movement, and the spread of
bacteria (30), it will be interesting to determine whether E.
tarda exploits microtubules through EseG for its entry into,
and movement in, fish cells.
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